CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Net Income (Loss) Available to Common Stockholders, Basic
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Net Income (Loss) Available to Common Stockholders, Basic of -$144.34 million for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-27 was -$276.56M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-27 was $54.42M, a 20.76% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-28 was $52.33M, a 41.85% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-29 was $25.47M, a 62.17% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$144.34M, a 1501.75% decline from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was $10.30M, a 97.83% decline from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was $474.62M, a 2.39% decline from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was $486.23M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2025-12-27 | -$276.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$222.13M derived: sum of 2 quarters · filed 2026-02-18 | -$169.81M derived: sum of 3 quarters · filed 2026-02-18 | -$144.34M 10-K · filed 2026-02-18 |
| 2025-09-27 | $54.42M 10-Q · filed 2025-11-05 | $106.75M derived: sum of 2 quarters · filed 2025-11-05 | $132.22M 10-Q · filed 2025-11-05 | -$83.48M derived: sum of 4 quarters · filed 2026-02-18 |
| 2025-06-28 | $52.33M 10-Q · filed 2025-08-06 | $77.80M 10-Q · filed 2025-08-06 | -$137.90M derived: sum of 3 quarters · filed 2026-02-18 | -$69.22M derived: sum of 4 quarters · filed 2026-02-18 |
| 2025-03-29 | $25.47M 10-Q · filed 2025-05-07 | -$190.23M derived: sum of 2 quarters · filed 2026-02-18 | -$121.55M derived: sum of 3 quarters · filed 2026-02-18 | -$31.56M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-12-28 | -$215.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$147.02M derived: sum of 2 quarters · filed 2026-02-18 | -$57.03M derived: sum of 3 quarters · filed 2026-02-18 | $10.30M 10-K · filed 2026-02-18 |
| 2024-09-28 | $68.68M 10-Q · filed 2025-11-05 | $158.67M derived: sum of 2 quarters · filed 2025-11-05 | $226.00M 10-Q · filed 2025-11-05 | $413.08M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-29 | $89.99M 10-Q · filed 2025-08-06 | $157.32M 10-Q · filed 2025-08-06 | $344.40M derived: sum of 3 quarters · filed 2026-02-18 | $431.79M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-30 | $67.33M 10-Q · filed 2025-05-07 | $254.41M derived: sum of 2 quarters · filed 2026-02-18 | $341.80M derived: sum of 3 quarters · filed 2026-02-18 | $438.82M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-30 | $187.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $274.47M derived: sum of 2 quarters · filed 2026-02-18 | $371.49M derived: sum of 3 quarters · filed 2026-02-18 | $474.62M 10-K · filed 2026-02-18 |
| 2023-09-30 | $87.39M 10-Q · filed 2024-11-06 | $184.41M derived: sum of 2 quarters · filed 2024-11-06 | $287.54M 10-Q · filed 2024-11-06 | |
| 2023-07-01 | $97.02M 10-Q · filed 2024-08-07 | $200.15M 10-Q · filed 2024-08-07 | ||
| 2023-04-01 | $103.13M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $486.23M 10-K · filed 2025-02-19 | |||
| 2017-12-30 | -$29.85M 10-K · filed 2018-02-13 | $22.63M derived: sum of 2 quarters · filed 2018-02-13 | $76.58M derived: sum of 3 quarters · filed 2018-02-13 | $123.36M derived: sum of 4 quarters · filed 2018-02-13 |
| 2017-09-30 | $52.47M 10-K · filed 2018-02-13 | $106.43M derived: sum of 2 quarters · filed 2018-02-13 | $153.20M derived: sum of 3 quarters · filed 2018-02-13 | $197.88M derived: sum of 4 quarters · filed 2018-02-13 |
| 2017-07-01 | $53.95M 10-K · filed 2018-02-13 | $100.73M derived: sum of 2 quarters · filed 2018-02-13 | $145.41M derived: sum of 3 quarters · filed 2018-02-13 | $183.15M derived: sum of 4 quarters · filed 2018-02-13 |
| 2017-04-01 | $46.78M 10-K · filed 2018-02-13 | $91.46M derived: sum of 2 quarters · filed 2018-02-13 | $129.19M derived: sum of 3 quarters · filed 2018-02-13 | $164.40M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-12-31 | $44.68M 10-K · filed 2018-02-13 | $82.42M derived: sum of 2 quarters · filed 2018-02-13 | $117.62M derived: sum of 3 quarters · filed 2018-02-13 | $154.76M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-09-24 | $37.73M 10-K · filed 2018-02-13 | $72.94M derived: sum of 2 quarters · filed 2018-02-13 | $110.08M derived: sum of 3 quarters · filed 2018-02-13 | $141.97M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-25 | $35.21M 10-K · filed 2018-02-13 | $72.35M derived: sum of 2 quarters · filed 2018-02-13 | $104.23M derived: sum of 3 quarters · filed 2018-02-13 | $141.61M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-26 | $37.14M 10-K · filed 2018-02-13 | $69.03M derived: sum of 2 quarters · filed 2018-02-13 | $106.41M derived: sum of 3 quarters · filed 2018-02-13 | $154.91M derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-26 | $31.88M 10-K · filed 2017-02-14 | $69.26M derived: sum of 2 quarters · filed 2017-02-14 | $117.77M derived: sum of 3 quarters · filed 2017-02-14 | $149.31M 10-K · filed 2016-02-12 |
| 2015-09-26 | $37.38M 10-K · filed 2017-02-14 | $85.89M derived: sum of 2 quarters · filed 2017-02-14 | $117.43M 10-Q · filed 2015-11-04 | $144.59M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-27 | $48.51M 10-K · filed 2017-02-14 | $80.05M 10-Q · filed 2015-07-30 | $107.22M derived: sum of 3 quarters · filed 2017-02-14 | $139.25M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-28 | $31.54M 10-K · filed 2017-02-14 | $58.71M derived: sum of 2 quarters · filed 2017-02-14 | $90.74M derived: sum of 3 quarters · filed 2017-02-14 | $126.01M derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-27 | $27.17M 10-K · filed 2016-02-12 | $59.20M derived: sum of 2 quarters · filed 2016-02-12 | $94.47M derived: sum of 3 quarters · filed 2016-02-12 | $126.70M 10-K · filed 2016-02-12 |
| 2014-09-27 | $32.04M 10-K · filed 2016-02-12 | $67.30M derived: sum of 2 quarters · filed 2016-02-12 | $99.53M 10-Q · filed 2015-11-04 | $118.63M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-28 | $35.26M 10-K · filed 2016-02-12 | $67.50M 10-Q · filed 2015-07-30 | $86.59M derived: sum of 3 quarters · filed 2016-02-12 | $117.46M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-29 | $32.23M 10-K · filed 2016-02-12 | $51.33M derived: sum of 2 quarters · filed 2016-02-12 | $82.20M derived: sum of 3 quarters · filed 2016-02-12 | $109.48M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-28 | $19.10M 10-K · filed 2015-02-17 | $49.97M derived: sum of 2 quarters · filed 2015-02-17 | $77.25M derived: sum of 3 quarters · filed 2015-02-17 | $102.83M 10-K · filed 2016-02-12 |
| 2013-09-28 | $30.87M 10-K · filed 2015-02-17 | $58.15M derived: sum of 2 quarters · filed 2015-02-17 | $83.73M 10-Q · filed 2014-10-30 | $102.14M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-06-29 | $27.28M 10-K · filed 2015-02-17 | $52.86M 10-Q · filed 2014-08-07 | $71.28M derived: sum of 3 quarters · filed 2015-02-17 | $93.25M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-03-30 | $25.58M 10-K · filed 2015-02-17 | $43.99M derived: sum of 2 quarters · filed 2015-02-17 | $65.97M derived: sum of 3 quarters · filed 2015-02-17 | $96.43M derived: sum of 4 quarters · filed 2015-02-17 |
| 2012-12-29 | $18.42M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $40.39M derived: sum of 2 quarters · filed 2014-02-25 | $70.86M derived: sum of 3 quarters · filed 2014-02-25 | $97.30M 10-K · filed 2014-02-25 |
| 2012-09-29 | $21.97M 10-Q · filed 2013-10-30 | $52.44M derived: sum of 2 quarters · filed 2013-10-30 | $78.88M 10-Q · filed 2013-10-30 | $105.99M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | $30.47M 10-Q · filed 2013-07-31 | $56.91M 10-Q · filed 2013-07-31 | $84.02M derived: sum of 3 quarters · filed 2014-02-25 | $102.82M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $26.44M 10-Q · filed 2013-05-08 | $53.55M derived: sum of 2 quarters · filed 2014-02-25 | $72.35M derived: sum of 3 quarters · filed 2014-02-25 | $104.67M derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | $27.11M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $45.91M derived: sum of 2 quarters · filed 2014-02-25 | $78.23M derived: sum of 3 quarters · filed 2014-02-25 | $109.57M 10-K · filed 2014-02-25 |
| 2011-09-24 | $18.80M 10-Q · filed 2012-11-01 | $51.12M derived: sum of 2 quarters · filed 2012-11-01 | $82.45M 10-Q · filed 2012-11-01 | -$261.11M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-25 | $32.32M 10-Q · filed 2012-08-07 | $63.65M 10-Q · filed 2012-08-07 | -$279.91M derived: sum of 3 quarters · filed 2013-02-27 | -$304.85M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-26 | $31.34M 10-Q · filed 2012-05-04 | -$312.23M derived: sum of 2 quarters · filed 2013-02-27 | -$337.17M derived: sum of 3 quarters · filed 2013-02-27 | |
| 2010-12-25 | -$343.56M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | -$368.50M derived: sum of 2 quarters · filed 2013-02-27 | -$336.67M 10-K · filed 2013-02-27 | |
| 2010-09-25 | -$24.94M 10-Q · filed 2011-11-02 | $6.89M 10-Q · filed 2011-11-02 | ||
| 2009-12-26 | $114.44M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |